FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes-February 2024-www.financetom.com

FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes

Nov 4, 2024 11:45 AM

Oct 31 (Reuters) - Independent advisers to the U.S. Food

and Drug Administration on Thursday voted against recommending

Lexicon Pharmaceuticals' ( LXRX ) add-on treatment to insulin

therapy for managing blood glucose levels in adults with type 1

diabetes and chronic kidney disease.

The panel voted 11 to 3 against recommending the drug,

chemically known as sotagliflozin.

Previous page： Suncor Energy beats third-quarter profit estimates Next page： Standard BioTools Q3 revenue falls

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Suncor Energy beats third-quarter profit estimates

Nov 4, 2025

Nov 4 (Reuters) - Canada's Suncor Energy ( SU ) beat third-quarter profit estimates on Tuesday, as the integrated oil and gas firm benefited from higher production. The company reported an adjusted profit of C$1.48 per share for the quarter ended September 30, compared with the analysts' average estimate of C$1.08 per share, according to data compiled by LSEG. ...

Standard BioTools Q3 revenue falls

Nov 4, 2025

Overview * Standard BioTools Q3 2025 revenue falls 11% yr/yr, reflecting declines in consumables and services * Adjusted EBITDA for Q3 2025 missed analyst expectations * Company implemented restructuring plan for $40 mln annualized cost savings Outlook * Company expects positive adjusted EBITDA in 2026 * Standard BioTools ( LAB ) anticipates $550 mln cash from Illumina transaction in 2026...

REIT Douglas Emmett's Q3 revenue misses expectations

Nov 4, 2025

Overview * Douglas Emmett ( DEI ) Q3 revenue missed analyst expectations, remaining flat year-over-year * Net loss attributable to common stockholders was $11 mln, down from a $5 mln profit Outlook * Douglas Emmett ( DEI ) expects 2025 Net Income Per Common Share - Diluted between $0.07 and $0.11 * Company narrows 2025 FFO per fully diluted share...

Health and wellness firm LifeVantage Q1 revenue misses estimates

Nov 4, 2025

Overview * LifeVantage ( LFVN ) fiscal Q1 revenue increased 0.7% yr/yr but missed analyst expectations * Adjusted EPS for fiscal Q1 rose to $0.18 from $0.15 a year ago * Company highlights strategic acquisition of LoveBiome as a pivotal milestone Outlook * Company reiterates FY 2026 revenue guidance of $225 mln to $240 mln * LifeVantage ( LFVN )...